Patients with tumours harbouring hypermethylated MGMT promoter had a median OS of 18.2 months compared to 11.4 months of MGMT unmethylated patients, HR2.10, 95% CI [1.68–2.62], p<0.001, Fig 2B. This evidence concerns the gene MGMT and neoplasm.